Literature DB >> 28798899

Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.

Brian E Goldhagen1, Raquel Goldhardt1.   

Abstract

PURPOSE OF REVIEW WHAT IS THE GOAL OF YOUR PAPER? WHAT QUESTIONS DID YOU SEEK TO ANSWER?: The goal of this paper is to provide a comprehensive review of the management options for central serous chorioretinopathy (CSCR). RECENT FINDINGS SUMMARIZE THE LATEST RESEARCH ON YOUR TOPIC: The majority of cases of acute CSCR may be managed with observation and cessation of corticosteroids, if possible, as well as life-style modifications including stress reduction and control of hypertension. The management of chronic disease is more challenging and may include either medication or laser-based treatment. SUMMARY WHAT ANSWERS DID YOU FIND? WHAT ARE THE MAJOR TAKEAWAYS/CONCLUSIONS OF YOUR EXAMINATION? WHAT’S THE IMPACT ON FUTURE RESEARCH?: Management of CSCR necessitates an individualized and selective treatment approach. There is overall poor evidence for the use of systemic and intravitreal medications. From this class of treatments, mineralocorticoid receptor antagonists appear to have the greatest potential. Although conventional thermal photocoagulation may be used in select cases, the most promising treatment options at this time for chronic CSCR are photodynamic therapy, either half-dose or half-fluence, and non-damaging (subthreshold) retinal laser therapy.

Entities:  

Keywords:  central serous chorioretinopathy; central serous retinopathy; cscr; csr; micropulse; photodynamic therapy; spironolactone; subthreshold laser

Year:  2017        PMID: 28798899      PMCID: PMC5546757          DOI: 10.1007/s40135-017-0133-4

Source DB:  PubMed          Journal:  Curr Ophthalmol Rep        ISSN: 2167-4868


  69 in total

1.  Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy.

Authors:  P Scholz; L Altay; S Fauser
Journal:  Eye (Lond)       Date:  2016-07-08       Impact factor: 3.775

2.  Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study.

Authors:  Myrte B Breukink; Danial Mohabati; Elon H C van Dijk; Anneke I den Hollander; Eiko K de Jong; Greet Dijkman; Jan E E Keunen; Carel B Hoyng; Camiel J F Boon
Journal:  Acta Ophthalmol       Date:  2016-05-06       Impact factor: 3.761

3.  Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy.

Authors:  Florian T A Kretz; Isabell Beger; Frank Koch; Katarrzyna Nowomiejska; Gerd U Auffarth; Michael J Koss
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-09       Impact factor: 1.300

4.  Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy.

Authors:  Hsin-Yu Liu; Chang-Hao Yang; Chung-May Yang; Tzyy-Chang Ho; Chang-Ping Lin; Yi-Ting Hsieh
Journal:  Am J Ophthalmol       Date:  2016-04-12       Impact factor: 5.258

5.  Central serous chorioretinopathy in younger and older adults.

Authors:  R F Spaide; L Campeas; A Haas; L A Yannuzzi; Y L Fisher; D R Guyer; J S Slakter; J A Sorenson; D A Orlock
Journal:  Ophthalmology       Date:  1996-12       Impact factor: 12.079

6.  Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.

Authors:  Elodie Bousquet; Talal Beydoun; Min Zhao; Leila Hassan; Olivier Offret; Francine Behar-Cohen
Journal:  Retina       Date:  2013 Nov-Dec       Impact factor: 4.256

7.  Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.

Authors:  San-Ni Chen; Jiunn-Feng Hwang; Li-Fang Tseng; Chun-Ju Lin
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

8.  COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Cheng-Kuo Cheng; Chun-Kai Chang; Chi-Hsien Peng
Journal:  Retina       Date:  2017-02       Impact factor: 4.256

9.  Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu; Wan-Leong Chan
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

10.  Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.

Authors:  Cihan Ünlü; Gurkan Erdogan; Tugba Aydogan; Betul Ilkay Sezgin Akcay; Esra Kardes; Gulunay Akcali Kiray; Tahir Kansu Bozkurt
Journal:  J Ophthalmic Vis Res       Date:  2016 Jan-Mar
View more
  2 in total

1.  Short-duration multiple-session subthreshold micropulse yellow laser (577 nm) for chronic central serous chorioretinopathy: results at 3 years.

Authors:  Yang Jae Kim; Si Yeol Kim; Seungmin Ha; Daruchi Moon; San Seong; Oh Woong Kwon; Han Sang Park
Journal:  Eye (Lond)       Date:  2019-01-04       Impact factor: 3.775

2.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.